Cell Therapy Market Size, Share & Trends Analysis Report By Therapy Type (Allogenic Therapies, Autologous Therapies, Non-Stem Cell Therapies), By Therapeutic Area (Oncology, Cardiovascular Disease, Musculoskeletal Disorders, Dermatology, Others), By Manufacturers (Biopharmaceutical and biotechnology companies, Pharmaceutical companies, CDMOs/CMOs, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Market Drivers

Expansion of Manufacturing Capacity for Autologous Therapies

The growth of autologous cell therapies is supported by the expansion of manufacturing capabilities, which presents as a significant driver for market growth.

• For example, in February 2024, AstraZeneca announced a $300 million project to establish a new cell-therapy facility in Rockville, Maryland, focused on producing T-cell therapies for clinical and commercial supply.

Such facility enhances production capacity, improves supply reliability, and facilitates wider access to autologous therapies.

Outcomes-Based Access for Cell Therapies

Cell therapies are highly expensive, often costing hundreds of thousands of dollars per patient, which creates major reimbursement and access challenges. To address this, outcomes-based payment models are being adopted, where reimbursement is directly tied to the therapy’s effectiveness in improving patient health.

• For example, in March 2024, the Centers for Medicare & Medicaid Services (CMS) launched the Cell and Gene Therapy (CGT) Access Model, enabling value-based agreements to expand access while controlling costs. 

This approach encourages the broader adoption of innovative cell therapies, which further enhances the market growth.

Market Restraint

High Cost and Manufacturing Complexity of Advanced Therapies

High cost and manufacturing complexity of advanced therapies, hinders the market growth as it limits the patient access.

• For example, in April 2025, the UK’s National Institute for Health and Care Excellence (NICE) initially declined to recommend BMS’s Abecma (idecabtagene vicleucel) for multiple myeloma due to concerns over its high price relative to clinical benefit.

Such factor highlights the ongoing affordability and reimbursement challenges, which further restrains the market growth.

Market Opportunities

Expanding the Scope of Cell Therapy Via the Expansion of Allogeneic Car-T Platforms

Expansion of allogeneic CAR-T platforms, presents as a significant market opportunity as it offers scalable, off-the-shelf treatments.

• For example, in January 2025, Allogene Therapeutics announced that the U.S. FDA cleared its Investigational New Drug (IND) application for ALLO-329, an allogeneic CAR-T candidate targeting autoimmune diseases.

Such factor acts as a significant step in expanding the scope of cell therapy applications beyond oncology into immune-mediated disorders.

Regional Insights

The North America region dominated the market with a revenue share of 57.35 % in 2025. The growth is attributed to factors such as strong presence of leading biotech and pharmaceutical companies, rapid adoption of CAR-T and stem cell therapies, supportive regulatory pathways from the U.S. FDA, significant R&D investments, and extensive clinical trial activity supported by advanced healthcare infrastructure and academic-industry collaborations.

Asia Pacific Market Trends

The Asia Pacific region is the fastest-growing region with a CAGR of 23.76 % during the forecast timeframe. The growth is attributed to factors such as a larger patient population, increasing government initiatives to strengthen biotechnology infrastructure, rising investment in advanced therapies by regional manufacturers, and rapid expansion of GMP-certified cell facilities.

Source: Straits Research Analysis

Country Analysis

U.S. Market Trends

The cell therapy industry in U.S. is widely driven by improved patient access, supported by regulatory as well as payer progress. For example, in July 2025, as per the U.S. Centers for Medicare & Medicaid Services, 84% of Medicaid beneficiaries with sickle cell disease are in states participating in CMS’s Cell therapy (CGT) Access Model.

UK Market Growth Factors

The market in the UK is propelling due to the rapid expansion of GMP manufacturing capacity, NHS adoption of CAR-T therapies and new regulations to enhance the manufacturing of cell therapies. For example, in July 2025, as per the Association for the Advancement of Blood and Biotherapies, the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) introduced “The Human Medicines (Amendment) (Modular Manufacture and Point of Care) Regulations 2025” for the on-site manufacture of advanced therapies, including cell therapies.

Germany Market Trends

In Germany, the market is driven by the strong industry and government initiatives. For example, in June 2024, as per DZIF, the government launched the National Strategy for Gene and Cell-Based Therapies to provide regulatory guidance and improve patient access nationwide.

China Market Growth Factors

The cell therapy market in China is fuelled by the strong manufacturing investments as well as regulatory reforms and focus of companies towards the development of advanced therapies. For example, in June 2025, CARsgen Therapeutics Holdings Limited announces that the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for satricabtagene autoleucel, an autologous CAR-T cell product for the treatment of Claudin18.2 in patients who have failed at least two prior lines of therapy.

India Market Trends

India continues to position itself in the cell therapy market, due to the rise of affordable home-grown CAR-T treatments. For example, in April 2024, as per the PIB, India launched its first homegrown genetic therapy, NexCAR19, developed via the collaborations between IIT Bombay, Tata Memorial Centre, and ImmunoACT.

Therapy Type Insights

The allogeneic cell therapy segment is anticipated to grow at a CAGR of 22.65 % from 2026 TO 2034. The growth is attributed to its scalability, off-the-shelf availability, and the ability to treat multiple patients from a single donor batch, which reduces production time and cost.

Application Insights

The oncology segment dominates the market with a revenue share of 38.17% in 2025. This growth is attributed to the strong pipelines as well as extensive clinical trials in oncology, which continue to attract the highest investments and collaborations globally.

Source: Straits Research Analysis

Manufacture Insights

The Biopharmaceutical and biotechnology companies segment dominated the market in 2025. This growth is attributed to their active collaborations with academic institutions and healthcare providers, the presence of supportive regulatory frameworks that enable faster product approvals, and the rising demand for personalized therapies.